{"id":"fondaparinux-sodium-arixtra","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Bleeding"},{"rate":"0.1-1%","effect":"Thrombocytopenia"},{"rate":"1-5%","effect":"Anemia"},{"rate":"1-5%","effect":"Injection site hematoma"},{"rate":"1-5%","effect":"Nausea"},{"rate":"1-5%","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fondaparinux is a synthetic pentasaccharide that binds to antithrombin III, enhancing its ability to inactivate Factor Xa. By blocking Factor Xa, it interrupts the intrinsic and common pathways of the coagulation cascade, preventing the conversion of prothrombin to thrombin and thus inhibiting clot formation. Unlike heparin, fondaparinux does not inhibit thrombin directly.","oneSentence":"Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:52.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute deep vein thrombosis (DVT) treatment"},{"name":"Acute pulmonary embolism (PE) treatment"},{"name":"Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery"}]},"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT06710184","phase":"PHASE4","title":"Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2025-05-01","conditions":"NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI), Acute Myocardial Infarction (AMI)","enrollment":5076},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT04539301","phase":"","title":"Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-04-01","conditions":"Anticoagulation, Venous Thromboembolism, Atrial Fibrillation","enrollment":2100},{"nctId":"NCT05001776","phase":"PHASE4","title":"Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein","status":"COMPLETED","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-08-16","conditions":"Superficial Vein Thrombosis, Endovenous Laser Ablation","enrollment":105},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT04406389","phase":"PHASE4","title":"Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-13","conditions":"COVID-19","enrollment":14},{"nctId":"NCT02699151","phase":"","title":"INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2016-04-14","conditions":"Superficial Vein Thrombosis","enrollment":1210},{"nctId":"NCT01499953","phase":"PHASE3","title":"Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2012-04","conditions":"Superficial Vein Thrombosis","enrollment":472},{"nctId":"NCT02219984","phase":"","title":"START-Register: Survey on Anticoagulated Patients Register","status":"RECRUITING","sponsor":"GUALTIERO PALARETI","startDate":"2011-10","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":15410},{"nctId":"NCT00789399","phase":"NA","title":"A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis","status":"TERMINATED","sponsor":"Prairie Education and Research Cooperative","startDate":"2009-11-19","conditions":"Deep Vein Thrombosis, Coronary Artery Bypass Surgery, Venous Thromboembolism","enrollment":78},{"nctId":"NCT04064489","phase":"NA","title":"Thromboembolic Risk Stratification by TRiP(Cast) Score to Guide Physicians in Preventive Treatment Prescriptions for Patients With Lower Limb Trauma Requiring Brace or castING.","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2020-06-16","conditions":"Lower Limb Trauma, Venous Thromboembolism, Stratification","enrollment":2123},{"nctId":"NCT00493896","phase":"PHASE3","title":"Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients","status":"TERMINATED","sponsor":"Eastern Virginia Medical School","startDate":"2007-07","conditions":"Venous Thromboembolism","enrollment":27},{"nctId":"NCT00521885","phase":"NA","title":"Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients","status":"TERMINATED","sponsor":"Lehigh Valley Hospital","startDate":"2007-09","conditions":"Venous Thrombosis","enrollment":1},{"nctId":"NCT04444700","phase":"PHASE3","title":"A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-07-04","conditions":"COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome","enrollment":465},{"nctId":"NCT01727401","phase":"PHASE4","title":"Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia","status":"TERMINATED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Medical Patient, Thrombocytopenia","enrollment":7},{"nctId":"NCT04671160","phase":"","title":"Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.","status":"UNKNOWN","sponsor":"Medical University of Gdansk","startDate":"2021-01-04","conditions":"Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis","enrollment":80},{"nctId":"NCT04359212","phase":"","title":"Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19","status":"COMPLETED","sponsor":"Quovadis Associazione","startDate":"2020-05-01","conditions":"COVID-19 Disease, Thromboembolism, Venous","enrollment":90},{"nctId":"NCT04246073","phase":"","title":"Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism","status":"UNKNOWN","sponsor":"Hellenic Society of Surgical Oncology","startDate":"2019-02-01","conditions":"Cancer, Cancer Diagnosis, Thromboembolism","enrollment":400},{"nctId":"NCT01895777","phase":"PHASE3","title":"Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-09-25","conditions":"Venous Thromboembolism","enrollment":267},{"nctId":"NCT04447378","phase":"PHASE4","title":"Safety of Fondaparinux as Post Partum Thromboprophylaxis","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2017-09-01","conditions":"Thromboembolism in the Puerperium","enrollment":60},{"nctId":"NCT04368377","phase":"PHASE2","title":"Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19","status":"COMPLETED","sponsor":"University of Milan","startDate":"2020-04-06","conditions":"Pneumonia, Viral, Corona Virus Infection, Respiratory Failure","enrollment":5},{"nctId":"NCT02234843","phase":"PHASE3","title":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-11-13","conditions":"Venous Thromboembolism","enrollment":500},{"nctId":"NCT00673439","phase":"PHASE2","title":"Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)","status":"TERMINATED","sponsor":"University of Louisville","startDate":"2007-11","conditions":"Heparin-Induced Thrombocytopenia","enrollment":3},{"nctId":"NCT02210819","phase":"","title":"Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-27","conditions":"Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":1987},{"nctId":"NCT00603824","phase":"PHASE4","title":"Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)","status":"WITHDRAWN","sponsor":"Methodist Healthcare","startDate":"2008-01","conditions":"Heparin-Induced Thrombocytopenia","enrollment":""},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT00894283","phase":"EARLY_PHASE1","title":"Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-06","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":198},{"nctId":"NCT01857583","phase":"PHASE3","title":"Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2012-03","conditions":"Venous Thromboembolism","enrollment":80},{"nctId":"NCT00320424","phase":"PHASE3","title":"Hip Fracture Study of GSK576428 (Fondaparinux Sodium)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-16","conditions":"Thromboembolism","enrollment":48},{"nctId":"NCT00320398","phase":"PHASE3","title":"Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-30","conditions":"Thrombosis, Venous","enrollment":114},{"nctId":"NCT00381888","phase":"PHASE2","title":"Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-01","conditions":"Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer","enrollment":44},{"nctId":"NCT01684423","phase":"PHASE2","title":"Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-19","conditions":"Venous Thrombosis","enrollment":64},{"nctId":"NCT01304238","phase":"","title":"Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute HIT II (Heparin-induced Thrombocytopenia Type II)","enrollment":195},{"nctId":"NCT01420809","phase":"","title":"Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Thromboembolism","enrollment":1280},{"nctId":"NCT01444612","phase":"","title":"Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02","conditions":"Thrombosis, Venous","enrollment":4068},{"nctId":"NCT00909064","phase":"PHASE4","title":"The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty","status":"COMPLETED","sponsor":"Paul Di Cesare,MD","startDate":"2009-06","conditions":"Total Knee Replacement","enrollment":114},{"nctId":"NCT00256100","phase":"NA","title":"Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.","status":"TERMINATED","sponsor":"Melbourne Health","startDate":"2004-06","conditions":"Renal Failure","enrollment":20},{"nctId":"NCT00539942","phase":"PHASE3","title":"Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2007-04","conditions":"Venous Thrombosis","enrollment":7},{"nctId":"NCT00790907","phase":"PHASE4","title":"Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute Coronary Syndrome","enrollment":3235},{"nctId":"NCT00443053","phase":"PHASE3","title":"Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Thrombosis, Venous","enrollment":3002},{"nctId":"NCT00378027","phase":"","title":"Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2006-08","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT01029743","phase":"","title":"Xarelto Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12","conditions":"Venous Thromboembolism","enrollment":3388},{"nctId":"NCT01619007","phase":"","title":"Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":5145},{"nctId":"NCT00981409","phase":"PHASE3","title":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Embolism, Pulmonary","enrollment":41},{"nctId":"NCT00911157","phase":"PHASE3","title":"The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06","conditions":"Thrombosis, Venous","enrollment":39},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092},{"nctId":"NCT00139815","phase":"PHASE3","title":"Michelangelo - Oasis 5","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Thromboembolism","enrollment":20078},{"nctId":"NCT00038961","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-11","conditions":"Thromboembolism","enrollment":1309},{"nctId":"NCT00423683","phase":"PHASE3","title":"Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2007-01","conditions":"Cancer, Thromboembolism","enrollment":64},{"nctId":"NCT00843492","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Thrombosis, Venous","enrollment":1351},{"nctId":"NCT00346879","phase":"PHASE1","title":"Study to Determine Effective Dosing of Fondaparinux in Obese Persons","status":"WITHDRAWN","sponsor":"Indiana University School of Medicine","startDate":"2006-08","conditions":"Morbid Obesity","enrollment":""},{"nctId":"NCT01428531","phase":"","title":"Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Ataxia","enrollment":200},{"nctId":"NCT01428544","phase":"","title":"Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03","conditions":"Ataxia","enrollment":5},{"nctId":"NCT01467583","phase":"PHASE4","title":"Fondaparinux in Critically Ill Patients With Renal Failure","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2011-11","conditions":"Venous Thromboembolism","enrollment":32},{"nctId":"NCT01064362","phase":"","title":"Hemorrhage Risk Prescribed Arixtra","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01","conditions":"Thrombosis, Venous","enrollment":13442},{"nctId":"NCT01406301","phase":"","title":"Fondaparinux EU-RMP (Adherence)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Acute Coronary Syndrome","enrollment":1},{"nctId":"NCT00412464","phase":"PHASE1","title":"Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2006-09","conditions":"Thrombosis, Heparin-induced Thrombocytopenia","enrollment":24},{"nctId":"NCT01390883","phase":"","title":"Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Cardiovascular Disease","enrollment":475},{"nctId":"NCT01691495","phase":"","title":"ARIXTRA® Adherence in SVT Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10","conditions":"Thrombosis, Venous","enrollment":1},{"nctId":"NCT00659399","phase":"PHASE1","title":"Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2008-01","conditions":"Ovarian Carcinoma","enrollment":""},{"nctId":"NCT01064596","phase":"","title":"Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2010-02","conditions":"Morbid Obesity, Obesity, Surgery","enrollment":40},{"nctId":"NCT01121770","phase":"PHASE1","title":"\"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction\"","status":"COMPLETED","sponsor":"Duke University","startDate":"2010-05","conditions":"Renal Insufficiency","enrollment":9},{"nctId":"NCT00483600","phase":"NA","title":"Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2007-08","conditions":"Kidney Diseases","enrollment":""},{"nctId":"NCT01390896","phase":"","title":"Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Cardiovascular Disease","enrollment":329},{"nctId":"NCT02154919","phase":"","title":"Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Beijing Shijitan Hospital, Capital Medical University","startDate":"2011-04","conditions":"Conservative Pharmacotherapy, Staged Percutaneous Coronary Intervention, Non-culprit Vessels","enrollment":306},{"nctId":"NCT01267305","phase":"NA","title":"The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2011-01","conditions":"Lung Neoplasms, Esophageal Neoplasms, Venous Thromboembolism","enrollment":362},{"nctId":"NCT01809054","phase":"PHASE4","title":"Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty","status":"COMPLETED","sponsor":"LifeBridge Health","startDate":"2012-04","conditions":"Primary Total Hip and Knee Arthroplasty","enrollment":54},{"nctId":"NCT00476216","phase":"PHASE1","title":"Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-09","conditions":"Non-Small Cell Lung Cancer, Venous Thromboembolism","enrollment":23},{"nctId":"NCT00531843","phase":"PHASE2, PHASE3","title":"The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients","status":"COMPLETED","sponsor":"Mary Knudson, M.D.","startDate":"2007-12","conditions":"Venous Thromboembolism","enrollment":105},{"nctId":"NCT00464087","phase":"PHASE3","title":"Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2007-06","conditions":"Acute Coronary Syndromes","enrollment":100},{"nctId":"NCT00377091","phase":"PHASE4","title":"Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2007-06","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT00881088","phase":"PHASE2, PHASE3","title":"Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures","status":"UNKNOWN","sponsor":"Red Cross Hospital Beverwijk","startDate":"2009-04","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":669},{"nctId":"NCT00911300","phase":"PHASE2","title":"Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08","conditions":"Fibrillation, Atrial","enrollment":349},{"nctId":"NCT01382550","phase":"","title":"Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.","status":"UNKNOWN","sponsor":"Federico II University","startDate":"1993-03","conditions":"Venous Thrombosis","enrollment":900},{"nctId":"NCT00927602","phase":"PHASE4","title":"Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency","status":"TERMINATED","sponsor":"Università degli Studi dell'Insubria","startDate":"2009-04","conditions":"Medical Patients, Renal Insufficiency","enrollment":206},{"nctId":"NCT00767559","phase":"NA","title":"Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery","status":"UNKNOWN","sponsor":"The New England Baptist Hospital","startDate":"2008-11","conditions":"Pulmonary Embolism","enrollment":330},{"nctId":"NCT01004939","phase":"","title":"Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03","conditions":"Thromboembolism, Venous Thromboembolism","enrollment":120},{"nctId":"NCT00555438","phase":"PHASE4","title":"Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2007-06","conditions":"Major Orthopaedic Surgery and Renal Impairment","enrollment":451},{"nctId":"NCT01101256","phase":"","title":"Determination of Residual Anticoagulatory Effects of Fondaparinux","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2010-04","conditions":"Anticoagulant Prophylaxis/Therapy","enrollment":110},{"nctId":"NCT00252005","phase":"PHASE2","title":"Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"Deep-Vein Thrombosis","enrollment":520},{"nctId":"NCT01063543","phase":"","title":"Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2004-09","conditions":"Orthopedic Surgery","enrollment":997},{"nctId":"NCT00060554","phase":"PHASE2","title":"A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Schering-Plough","startDate":"2003-04","conditions":"Myocardial Infarction, Coronary Disease","enrollment":300},{"nctId":"NCT00549705","phase":"","title":"Registry of Hospitalized Patients Treated With Fondaparinux","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2007-07","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":220},{"nctId":"NCT00510432","phase":"","title":"Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2007-04","conditions":"Allergy","enrollment":500},{"nctId":"NCT00333021","phase":"PHASE3","title":"Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Venous Thromboembolism","enrollment":127},{"nctId":"NCT00327106","phase":"PHASE3","title":"Tranexamic Acid in HIp Fracture Surgery (THIF Study)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2005-04","conditions":"Hip Fracture","enrollment":110},{"nctId":"NCT00413504","phase":"NA","title":"Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-04","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":30},{"nctId":"NCT00436787","phase":"PHASE2","title":"Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-02","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":21},{"nctId":"NCT00474591","phase":"PHASE3","title":"Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"","conditions":"Coronary Bypass Graft Failure/Occlusion","enrollment":100},{"nctId":"NCT00424281","phase":"","title":"Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2007-02","conditions":"ICU Patients 18 Years or Older.","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL WALL HAEMATOMA"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"DRUG ADMINISTRATION ERROR"},{"count":1,"reaction":"FALSE POSITIVE INVESTIGATION RESULT"},{"count":1,"reaction":"GASTRITIS"},{"count":1,"reaction":"HAEMORRHAGE"},{"count":1,"reaction":"INTRA-ABDOMINAL HAEMORRHAGE"},{"count":1,"reaction":"LEUKOCYTOSIS"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":94,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arixtra"],"phase":"marketed","status":"active","brandName":"Fondaparinux Sodium (Arixtra)","genericName":"Fondaparinux Sodium (Arixtra)","companyName":"Paul Di Cesare,MD","companyId":"paul-di-cesare-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation. Used for Acute deep vein thrombosis (DVT) treatment, Acute pulmonary embolism (PE) treatment, Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}